228401-16-9

Basic information

• Product Name: Methanesulfonic acid, trifluoro-, 4-(1,1-dimethylethyl)-2-nitrophenyl ester
• CAS NO: 228401-16-9
• Molecular Formula: C11H12F3NO5S
• Molecular Weight: 327.281
• Mol File: 228401-16-9.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: Methanesulfonic acid, trifluoro-, 4-(1,1-dimethylethyl)-2-nitrophenyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonic acid, trifluoro-, 4-(1,1-dimethylethyl)-2-nitrophenyl ester(228401-16-9)
• EPA Substance Registry System: Methanesulfonic acid, trifluoro-, 4-(1,1-dimethylethyl)-2-nitrophenyl ester(228401-16-9)

Safety Data

• Hazardous Substances Data: 228401-16-9(Hazardous Substances Data)

Upstream product

• 358-23-6 trifluoromethylsulfonic anhydride 
• 3279-07-0 4-tert-butyl-2-nitrophenol 
• 421-83-0 trifluoromethane sulfonyl chloride 

Downstream Products

• 340825-36-7 4-tert-butyl-2-nitro-N-[2-(morpholin-4-yl)ethyl]aniline 
• 340825-34-5 3-bromo-5-tert-butyl-2-[2-(morpholin-4-yl)ethylamino]aniline 
• 1147530-71-9 (4-tert-butyl-2-nitrophenylethynyl)trimethylsilane 
• 855304-77-7 4-tert-butyl-1-methylsulfanyl-2-nitro-benzene 
• 3279-07-0 4-tert-butyl-2-nitrophenol 

Relevant articles and documents

Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas

This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

1,2,3-TRIAZOLE AMIDE DERIVATIVES AS INHIBITORS OF CYTOKINE PRODUCTION

Disclosed are compounds of formula (I), where Ar1, X, R3, R4, R5 and R6 are defined herein. The compounds of the invention inhibit production of cytokines and are thus useful for treating cytokine mediated diseases. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

INHIBITION OF p38 KINASE USING SYMMETRICAL AND UNSYMMETRICAL DIPHENYL UREAS

This invention relates to the use of a group of aryl ureas in treating cytokine mediated diseases and proteolytic enzyme mediated diseases, and pharmaceutical compositions for use in such therapy.